1. Home
  2. CBUS vs NERV Comparison

CBUS vs NERV Comparison

Compare CBUS & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cibus Inc.

CBUS

Cibus Inc.

N/A

Current Price

$1.23

Market Cap

116.2M

Sector

Industrials

ML Signal

N/A

NERV

Minerva Neurosciences Inc

N/A

Current Price

$2.13

Market Cap

108.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CBUS
NERV
Founded
2010
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.2M
108.6M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
CBUS
NERV
Price
$1.23
$2.13
Analyst Decision
Buy
Buy
Analyst Count
3
3
Target Price
★ $12.00
$10.33
AVG Volume (30 Days)
108.8K
★ 167.7K
Earning Date
11-12-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 74.33
N/A
EPS
N/A
★ N/A
Revenue
$3,639,000.00
★ $41,175,600.00
Revenue This Year
$39.09
N/A
Revenue Next Year
$107.71
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.02
$1.96
52 Week High
$4.19
$8.80

Technical Indicators

Market Signals
Indicator
CBUS
NERV
Relative Strength Index (RSI) 45.80 34.63
Support Level N/A $1.96
Resistance Level $1.65 $2.71
Average True Range (ATR) 0.17 0.24
MACD 0.02 0.01
Stochastic Oscillator 42.58 4.17

Price Performance

Historical Comparison
CBUS
NERV

About CBUS Cibus Inc.

Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

Share on Social Networks: